LONDON, 27 June 2007 – Hikma Pharmaceuticals PLC (”Hikma”) (LSE: HIK) (DIFX: HIK), the multinational pharmaceuticals group, has seen continuing growth in the year to date and expects first half revenues to be up approximately 40% and first half gross margins to be around 50%.
